Ad-hoc-Mitteilung gemäss Art. 53 KR Die exklusive Lizenzvereinbarung umfasst eine Vorauszahlung in Höhe von 40 Millionen US-Dollar, bestehend aus 30 Millionen US-Dollar in bar und einer Kapitalbeteiligung in Höhe von 10 Millionen US-Dollar zu einem Preis von 14,91 CHF pro Aktie, was einem Aufschlag von 20 % auf den 30-Tage-VWAP entspricht. Pratteln, Schweiz, 8. Januar 2026 – Santhera Pharmaceuticals (SIX: SANN) gibt bekannt, dass es eine exklusive Lizenzvereinbarung mit Nxera Pharma UK Ltd. (“Nxera”) über d ...

Japan-based Nxera Pharma is seeking buyers for its Phase II-ready schizophrenia programme after Boehringer Ingelheim decided not to exercise a licensing option. Boehringer Ingelheim, which held exclusive rights to license the neurological disorder portfolio of GPR52 agonists, did not provide further information to Nxera. Rights to the programme will now revert to the Japanese biotech. Nxera said it is now exploring strategic opportunities for the programme, including a licensing partnership with a major ...

Smiley said: “One of the main reasons that global companies are so engaged in China right now is the fact that you can find an early clinical programme for less total value exchange than in the US or Europe.As 2026 approaches, Josh Smiley, president and COO of US-China biopharma Zai Labs, predicts that dealmaking between China and the West will continue to grow, with deal volume rising in tandem.In the last five years, there has been a sizable increase in high-value deals between the West and China, with 20 ...

Core Insights - Amarin's shares surged 27.3% following the announcement of an exclusive long-term licensing agreement with Recordati to commercialize its drug Vazkepa across 59 EU countries [1][6]. Licensing Agreement Details - The agreement grants Recordati exclusive rights to market Vazkepa in Europe, with Amarin receiving an upfront payment of $25 million and potential milestone payments of up to $150 million based on sales targets [4][6]. - Amarin expects to achieve approximately $70 million in cost savings over the next 12 months as part of a strategy to enhance growth and reduce operational costs [3][7]. Product and Market Context - Vazkepa is approved in the EU for treating severe hypertriglyceridemia and reducing cardiovascular event risks, similar to its approval in the U.S. under the name Vascepa [2]. - The drug is protected by patents until 2039 in the EU, which supports its market expansion efforts [3]. Financial Position and Growth Strategy - The licensing deal strengthens Amarin's cash position, with nearly $300 million in cash and no debt as of March-end [7]. - The partnership with Recordati is expected to enhance Amarin's financial strength and accelerate its path to positive cash flow through new revenue opportunities [7][8]. Industry Position - Amarin's stock has increased by 65.3% year-to-date, contrasting with a 4.2% decline in the industry [5]. - Recordati's established cardiovascular portfolio, which includes treatments for hypertension and heart failure, positions it well to expand the reach of Vazkepa [8].

Core Insights - Insiders' stock purchases can signal confidence in a company's future prospects, potentially influencing other investors' decisions [1][2] Company Overview - Summit Therapeutics is a clinical-stage biotech company with a market capitalization of $20 billion, which is notably high for a company without any products on the market [4] - The company's leading candidate, ivonescimab, has shown promising results, outperforming Merck's Keytruda in a phase 3 clinical trial for non-small cell lung cancer (NSCLC) [4][5] Recent Developments - On April 8, 2023, co-CEOs Robert Duggan and Maky Zanganeh exercised warrants to purchase nearly 4 million shares each at $1.58 per share, indicating their confidence in the company's future [3][4] - The fast-track designation from the U.S. FDA for ivonescimab in NSCLC highlights the drug's potential to address significant unmet medical needs [5] Drug Potential - Ivonescimab is undergoing multiple late-stage studies in the U.S. and has the potential to target various cancer indications, similar to Keytruda [6] - The drug was licensed from Akeso, a China-based biopharma, allowing Summit to market it in key regions like the U.S. and Europe [7] Leadership and Strategy - The leadership's ability to license a potentially blockbuster drug reflects positively on the company's strategic direction and management capabilities [8]

Core Viewpoint - Merck has entered into an exclusive licensing agreement with Jiangsu Hengrui Pharmaceuticals for the development and marketing of HRS-5346, an investigational oral small-molecule Lipoprotein(a) inhibitor [1][2]. Group 1: Licensing Deal Details - Merck will acquire global rights (excluding Greater China) for HRS-5346, paying an upfront cash payment of $200 million and up to $1.77 billion in milestone payments, along with royalties on future sales [2][3]. - The deal is expected to close in the second quarter, pending customary closing conditions and regulatory approvals [3]. Group 2: Health Implications - Elevated levels of Lipoprotein(a) are a significant risk factor for cardiovascular diseases, affecting approximately 1.4 billion people globally [4]. Group 3: Strategic Context - This licensing agreement marks Merck's third collaboration with Chinese biotech firms, following previous multi-billion dollar deals with Hansoh Pharma and LaNova Medicines [7]. - The strategy aims to diversify Merck's revenue base, which is heavily reliant on Keytruda, accounting for nearly 46% of total revenues in 2024 [8]. - The trend of big pharma companies seeking partnerships in China reflects a broader industry movement towards accessing new drugs at attractive valuations [9].